The Rise Of Japanese Pharma Dealmakers
Executive Summary
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
You may also be interested in...
With New Fund, Mitsubishi And Daiichi Sankyo Aim To Boost Japan’s Start-Ups
Daiichi Sankyo and Mitsubishi UFJ announced a modest seed fund in September, but for Japan’s academia spin-offs, the options remain limited.
With New Fund, Mitsubishi And Daiichi Aim To Boost Japan’s Start-Ups
Daiichi Sankyo and Mitsubishi UFJ announced a modest seed fund in September, but for Japan’s academia spin-offs, the options remain limited.
The Hype And Hope Of Cancer Stem Cell Therapeutics
A wave of recent deals demonstrates a growing belief in the potential cancer stem cells might offer for more effective cancer therapies. Some say there’s more hope and hype than science behind the activity. As the science unfolds, fundamental questions have yet to be answered about the pathway to products, especially as drug developers train their lines of sight on solid tumors.